Publications

Search our bibliography using the filters on the right-hand side.

Displaying 151 through 200 of 341 publications.

Maurer M, Houghton K, Stull D, Mcbride D, Janssens N, Heinrichs N, Antonova E, Balp MM, Khalil S. Characterization of responders to omalizumab: exploratory analysis of phase III data from patients with chronic spontaneous urticaria. Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 13, 2016. Vienna, Austria.

Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 2016 SDPA Annual Summer Dermatology Conference; June 2016. Austin, TX. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.

Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 4th Annual Maui Derm NP+PA Summer Meeting; June 2016. Colorado Springs, CO. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.

Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality-of- life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the SDPA Annual Summer Dermatology Conference 2016; June 2016. Austin, TX. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.

Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the 4th Annual Maui Derm NP+PA Summer Meeting; June 2016. Colorado Springs, CO. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.

Mordin M, Haydysch E, Graham-Clarke CP, Gnanasakthy A, Nikai E. Patient perceptions of psoriasis: a review of the survey literature by geography. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A126-7.

Hawe E, Mcbride D, Balp MM, Tian H, Halliday A, Stull DE. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics. 2016 May;34(5):521-7. doi: 10.1007/s40273-015-0375-7

Mcbride D, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst A, Lacour J-P, Lynde C, Marsland A, Nakonechna A, Ortiz De Frutoz FJ, Oude Elberink JNG, Proctor C, Sussman G, Weller K, Maurer M. ASSURE-CSU: assessing the impact of chronic spontaneous/idiopathic urticaria on work productivity and activity. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A124-5.

Korman N, Sofen H, Rich P, Fretzin S, Zhao Y, Herrera V, Mordin M, Williams N, Nyirady J, Tyring S. Secukinumab provides more effective relief from psoriasis impact on personal relationships and influence on clothes worn than etanercept and placebo. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1049

Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1050

Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB272. doi: 10.1016/j.jaad.2016.02.1051

Puig L, Mordin M, Mollon P, Williams N, Fox T, Papavassilis C, Strober B. Disease burden in patients with severe psoriasis. Poster presented at the American Academy of Dermatology 74th Annual Meeting; March 4, 2016. Washington, DC. [abstract] J Am Acad Dermatol. 2016 May; 74(5 (Supplement 1)):AB243. doi: 10.1016/j.jaad.2016.02.952

Graham CN, Miles L, Mcbride D, Zhao Y, Herrera V. Estimation of annual indirect costs associated with moderate-to-severe plaque psoriasis in the United States. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA.

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassils C, Nyirady J, Lebwohl M. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401-7. doi: 10.1111/ijd.13236

Stull DE, Mcbride D, Houghton K, Finlay AY, Gnanasakthy A, Balp MM. Assessing changes in chronic spontaneous/idiopathic urticaria: comparisons of patient-reported outcomes using latent growth modeling. Adv Ther. 2016 Feb;33(2):214-24. doi: 10.1007/s12325-016-0282-0

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 15th Annual Caribbean Dermatology Symposium; January 26, 2016. Grand Cayman. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 12th Annual Maui Derm for Dermatologists 2016 Conference; January 25, 2016. Maui, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the Winter Clinical Dermatology Conference; January 15, 2016. Kauai, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatolog Trea. 2016 Jan;27(1):19-26. doi: 10.3109/09546634.2015.1044492

Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 12, 2015. Orlando, FL. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

McLeod L, Mallya AG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials. Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Graham CN, Mcbride D, Miles L, Kneidl J, Mollon P. Estimation of indirect (work-related productivity) costs associated with moderate-to-severe plaque psoriasis in Germany. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 2015. Orlando, FL. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

DiBenedetti D, Baranowski E, Zelt S, Reynolds M, Sherrill B. Assessing United States patient and dermatologist experiences with severe chronic hand eczema. J Clin Aesthet Dermatol. 2015 Nov;8(11):19-27.

Mcbride D, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Roth N, Weller K, Maurer M, Koenders J, Knulst AC, Elberink JN, Halliday A, Alexopoulos ST, Nakonechna A, Abouzakouk M, Sweeney C, Radder C, Wolin D, Hollis K, Tian H, Balp MM, Grattan C. First real-world study assessing health utility values for chronic spontaneous/idiopathic urticaria using the EQ-5D. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Balp MM, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Rothe N, Weller K, Maurer M, Koenders J, Knulst AC, Halliday A, Alexopoulos ST, Nakonechna A, Grattan C, Abouzakouk M, Sweeney C, Radder C, Wolin D, Mcbride D, Hollis K, Tian H, Elberink JN. Work productivity and activity impairment among chronic spontaneous/idiopathic urticaria patients: results from the first international burden of illness study (ASSURE-CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalised infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015 Nov;173(5):1183-90. doi: 10.1111/bjd.14068

Tian H, Chambenoit O, Chiva-Razavi S, Lynde C, Sussman G, Chapman-Rothe N, Weller K, Koenders J, Knulst AC, Elberink JN, Halliday A, Alexopoulos ST, Nakonechna A, Grattan C, Abouzakouk M, Sweeney C, Radder C, Wolin D, Mcbride D, Hollis K, Balp MM, Maurer M. Healthcare resource utilisation among chronic spontaneous/idiopathic urticaria patients- findings from the first international burden of illness study (ASSURE-CSU). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Klimes J, Mollon P, Graham C, Rajnoch J, Dostal F, Skalicky D, Jordan P, Depta J. Cost-effectiveness analysis of secukinumab compared to ustekinumab in the treatment of moderate to severe plaque psoriasis in the Czech Republic. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

D'Ausilio A, Aiello A, Daniel F, Graham C, Roccia A, Toumi M. A cost-effectiveness analysis of secukinumab 300 mg vs current therapies for the treatment of moderate to severe plaque psoriasis in Italy. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

Edson-Heredia E, Barrows S, Masaquel C, Nikai E, Mallbris L, Puig L. The value of achieving complete or near complete resolution of psoriasis. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Sherif B, Mollon P, Williams N, Fox T, Papavassilis C, Strober B, Gottlieb A. Secukinumab relieves pain and anxiety in psoriasis: results of two phase 3 trials. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Elewski B, Williams N, Mollon P, Sherif B, Fox T, Papavassilis C, Puig L. Psoriasis skin clearance is associated with patient-reported impact. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Strober B, Mordin M, Mollon, P, Williams N, Fox T, Papavassilis C, Lebwohl M. Secukinumab demonstrates greater impact on patient global impression of change than etanercept in moderate to severe psoriasis. Poster presented at the 24th European Academy of Dermatology and Venereology Congress; October 2015. Copenhagen, Denmark.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Weller K, Grattan C, Abuzakouk M, Berard F, Sussman G, Lynde C, Canonica GW, Knulst A, Ortiz De Frutos J, Nakonechna A, Gimenez-Arnau A, Oude Elberink JNG, Balp MM, Khalil S, Tian H, Hollis K, Sweeney C, Radder C, Mcbride D, Maurer M. Patient profile from the first international burden of illness study in inadequately controlled chronic spontaneous urticaria: ASSURE-CSU. Poster presented at the 24th European Academy of Dermatology and Venereology (EADV) Congress; October 2015. Copenhagen, Denmark.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials. Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Sussman G, Lynde C, Zanganeh S, Lacuesta G, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA, McBride DW, Westlund RE, Sweeney CT, Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: an analysis of the diagnosis and treatment of patients with antihistamine-refractory CSU. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada. [abstract] Clin Transl Allergy. 2015 Aug 17; 5(29):1-7. doi: 10.1186/s13601-015-0072-9

Weller K, Maurer M, Grattan C, Nakonechna A, Abuzakouk M, Bérard F, Sussman G, Giménez-Arnau AM, Ortiz De Frutos J, Knulst A, Canonica GW, Hollis K, Mcbride D, Balp MM. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy. 2015 Aug 17;17(5):29.

McLeod L, Mallya UG, Fox T, Zhao Y, Mordin M, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L, Mordin M, Nelson L, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.

Sussman G, Lynde C, Kanani A, Hebert J, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA, McBride DW, Westlund RE, Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: redefining our understanding of the clinical characteristics of patients with CSU/CIU refractory to H1- antihistamines. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.